Posted on June 10, 2012 Updated on June 10, 2012
This entry was posted in Radiology Physics.
I truly appreciate this article post.Really looking forward to read more. Want more.
I loved your blog post. Great.
truck driver resume
Great blog article. Cool.
social media guidelines
I am so grateful for your post.Really looking forward to read more. Great.
truck driver resume
I value the article post.Thanks Again. Want more.
personalized gift cards
Thank you ever so for you blog article. Great.
Modlin Car Hire
Very good blog.Much thanks again. Great.
Great, thanks for sharing this article post.Really thank you! Will read on…
dal sol organization
Really enjoyed this article. Want more.
Hey, thanks for the post.Thanks Again. Awesome.
H Pylori Symptoms
Say, you got a nice blog.Really looking forward to read more. Really Cool.
Really enjoyed this post.Thanks Again. Really Great.
Click Here For Video
Thanks a lot for the article.Thanks Again. Really Great.
Great, thanks for sharing this post.Thanks Again. Keep writing.
Im grateful for the post.Thanks Again. Will read on…
neonato cameretta design
Thanks so much for the article post.Thanks Again. Really Great.
Fantastic blog.Thanks Again. Fantastic.
best tablet for the money
SNM changes its name to include molecular imaging
The Society of Nuclear Medicine (SNM) membership voted June 11 for the proposal to change the name of the organization to the Society of Nuclear Medicine and Molecular Imaging (SNMMI). In an official vote held at the business meeting portion of the SNM 2012 annual meeting in Miami, more than two-thirds of SNM members present voted affirmatively to change the society’s name.
“Over the past five years, SNM has made a concerted effort to embrace other modalities that, like nuclear medicine, utilize the tracer principle,” said George M. Segall, MD, SNM immediate past president. “The name ‘Society of Nuclear Medicine and Molecular Imaging’ retains our rich history and identity while recognizing the growing diversity in our field. Retaining ‘nuclear medicine’ as part of the society’s name also recognizes the therapeutic, medicinal aspects of nuclear medicine.”
SNM undertook a process to engage its members, providing pros and cons of changing the name and soliciting feedback. In January, the SNM house of delegates passed an amendment to the SNM bylaws that would change the society’s name to the “Society of Nuclear Medicine and Molecular Imaging.” The final step was this membership vote at the annual meeting.
“Changing our name is part of the natural progression of the organization to embrace molecular imaging,” said Frederic H. Fahey, DSc, SNM president and co-chair of the SNM Name Change Task Force. “We will continue to engage in activities to promote both nuclear medicine and molecular imaging. As an organization we now stand prepared to lead the way in translating novel imaging and therapeutic strategies for the new era of molecular and personalized medicine.”
Search + destroy isotope extends survival for prostate cancer
MIAMI—Radium-223 chloride radioisotope therapy, a new approach to the treatment of bone metastases, boosted survival, delayed complications and was well-tolerated, according to an interim analysis of the ALSYMPCA trial presented at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. “This represents a real breakthrough in the management of late-stage prostate cancer,” said Valerie Lewington, BM, MSc, professor of clinical therapeutic nuclear medicine at King’s College in London.
Radium-223 chloride (Ra-223) seeks out bone metastases with alpha particles that are deadly to tumors. Ra-223 has a short range of penetration of alpha particles, sparing nearby healthy tissues and bone marrow.
“Radium-223 offers a completely new approach to the treatment of bone metastases. It systemically treats multiple sites of disease simultaneously and is usually very well tolerated. Serious side effects are unusual, and the risk of bone marrow suppression is low even in patients who have been heavily pretreated with chemotherapy,” said Lewington. ALSYMPCA ((ALpharadin in SYMptomatic Prostate Cancer) focuses on castration-resistant prostate cancer, which is typically characterized by extensive skeletal metastases that are resistant to treatment.
The double-blind study randomized 921 patients in more than 100 centers in 19 countries with two or more bone metastases to Ra-223 or normal saline. Patients received six injections at four-week intervals. Ra-223 patients survived an average of 3.6 months longer than patients who received the placebo. In addition to prolonged survival, those treated with Ra-223 also experienced delayed onset of complications due to bone metastases. The average delay was 5.5 months, according to researchers.
The researchers monitored patients via bone scans and PET.
An expanded access program is underway in the U.S. and a similar program is expected to open in Europe in 2012. Further clinical trials are also being considered. Formal regulatory approval will be sought in mid-2012 in both the U.S. and Europe.
In September 2009, Bayer HealthCare signed an agreement with Algeta for the development and commercialization of Ra-223 dichloride for $800 million. Under the terms of the agreement, Bayer will develop, apply for global health authority approvals, and commercialize Ra-223 dichloride globally. In April, Algeta exercised its option to co-promote Ra-223 dichloride for the treatment of castration-resistant prostate cancer patients with bone metastases in the U.S., in accordance with the agreement with Bayer.
Ra-223 dichloride is an investigational agent and is not approved by the FDA, the European Medicines Agency or other health authorities. Bayer plans to file radium-223 dichloride with regulatory authorities based on the ALSYMPCA data in the second half of 2012.
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account. ( Log Out / Change )
You are commenting using your Twitter account. ( Log Out / Change )
You are commenting using your Facebook account. ( Log Out / Change )
You are commenting using your Google+ account. ( Log Out / Change )
Connecting to %s
Notify me of new comments via email.
Notify me of new posts via email.